Diabetes drug metformin may lower glaucoma risk

The diabetes drug metformin was linked to a lower risk of developing the eye condition glaucoma in a new study.
People who took the most metformin during the 10-year study period had a 25 percent reduced risk of glaucoma compared with people not taking the drug, researchers found.
"Glaucoma is a leading cause of blindness worldwide and classic open-angle glaucoma develops in late middle age or late age. So we hypothesized that a drug that mimics caloric restriction, such as metformin, might reduce the risk of glaucoma," said lead researcher Julia Richards, a professor of ophthalmology and visual sciences at the University of Michigan in Ann Arbor.
Exactly how metformin might reduce the risk of glaucoma isn't known, the researchers said. And, while this study found an association between metformin use and lower glaucoma risk, it wasn't designed to prove a cause-and-effect relationship.
Dr. Mark Fromer, an ophthalmologist at Lenox Hill Hospital in New York City, explained that glaucoma is caused by too much fluid in the eye, when fluid doesn't drain adequately, or when the blood vessels in the optic nerve are damaged. "Somehow metformin is affecting one of those conditions," he said.
Fromer pointed out that although the results of this study are impressive, using metformin to prevent or treat glaucoma in non-diabetic patients is problematic. Metformin could drop blood sugar too low in people without diabetes, he said.
"People without diabetes should not be taking metformin," he said. "If not monitored carefully by a doctor, it can have significant consequences," said Fromer, who was not involved with the study.
    Medicinenet.com

Richards, however, said that it might be possible to use metformin as a treatment for glaucoma even in people without diabetes.
   

 

Diabetes drug metformin may lower glaucoma risk

The diabetes drug metformin was linked to a lower risk of developing the eye condition glaucoma in a new study. People who took the most metformin during the 10-year study period had a 25 percent reduced risk of glaucoma compared with people not taking the drug, researchers found. Glaucoma is a leading cause of blindness worldwide and classic open-angle glaucoma develops in late middle age or late age. So we hypothesized that a drug that mimics caloric restriction, such as metformin, might reduce the risk of glaucoma, said lead researcher Julia Richards, a professor of ophthalmology and visual sciences at the University of Michigan in Ann Arbor. Exactly how metformin might reduce the risk of glaucoma isnt known, the researchers said. And, while this study found an association between metformin use and lower glaucoma risk, it wasnt designed to prove a cause-and-effect relationship. Dr. Mark Fromer, an ophthalmologist at Lenox Hill Hospital in New York City, explained that glaucoma is caused by too much fluid in the eye, when fluid doesnt drain adequately, or when the blood vessels in the optic nerve are damaged. Somehow metformin is affecting one of those conditions, he said. Fromer pointed out that although the results of this study are impressive, using metformin to prevent or treat glaucoma in non-diabetic patients is problematic. Metformin could drop blood sugar too low in people without diabetes, he said. People without diabetes should not be taking metformin, he said. If not monitored carefully by a doctor, it can have significant consequences, said Fromer, who was not involved with the study. Medicinenet.com Richards, however, said that it might be possible to use metformin as a treatment for glaucoma even in people without diabetes.